Merck buys Prometheus Biosciences (2023)
Merck agreed to pay about $10.8 billion for Prometheus Biosciences, a clinical-stage biotech with a late-stage immune-disease antibody. The price was a 75% premium on Prometheus's share price.
The deal closed later in 2023, one of the year's biggest biotech acquisitions.
It set a benchmark for what large drugmakers will pay for de-risked immunology assets to refill pipelines.
It shows the price range MoonLake could command, and why analysts see a sale as a live outcome once late-stage data land.
